Insider

GSK plc

GSK Salud · 2 análisis

Qué cambió

Qué cambió

GSK receives recommendation for Bexsero booster dose

The European Medicines Agency recommended adding the option of a Bexsero vaccine booster dose for individuals aged 10 years and older. The change applies to patients who completed primary immunization at least two years earlier.

· GSK plc

Historial de la empresa

Octubre 2026

GSK plc: 12 recorded developments from 7 official sources in 2026-10.

  • 2026-09-22: An Independent Non-Executive Director purchased 936 Ordinary Shares of GSK plc at £18.8100 per share. Fuente
  • 2026-09-24: Maya Martinez-Davis, President, US, acquired notional ADS within her GSK Executive Supplemental Savings Plan account. Fuente
  • 2026-09-24: The transaction involved a price of $50.7200 and a volume of 9.414 American Depositary Shares (ADS). Fuente
  • 2026-09-24: The transaction is a single transaction with no aggregated volume or price information applicable. Fuente
  • 2026-10-01: The total number of voting rights figure may be used by shareholders as the denominator for calculations to determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparen Fuente
  • 2026-10-06: The notification covers the date range from 7 August 2026 to 2 October 2026 for the admission of securities to trading. Fuente
  • 2026-10-08: Wendy Becker, an independent Non-Executive Director of GSK plc, has been appointed as a Non-Executive Director of Tesco PLC with effect from 1 November 2026. Fuente
  • 2026-10-13: Acquisition of Ordinary Shares under the Company's Share Reward Plan at a price of £17.6539 for a volume of 7 (partnership shares) and £17.6539 for a volume of 7 (matching shares). Fuente
  • 2026-10-14: Shobie Ramakrishnan, Chief Digital and Technology Officer, has an interest in American Depositary Shares (‘ADS’) of GSK plc Fuente
  • 2026-10-14: David Redfern, President, Corporate Development, has an interest in Ordinary shares of 31 ¼ pence each (Ordinary Shares) of GSK plc Fuente
  • 2026-10-14: David Redfern, President, Corporate Development, increased notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan Fuente
  • 2026-10-14: Julie Brown acquired Ordinary Shares following the re-investment of dividends paid on 8 October 2026 on Ordinary Shares held in the Company’s Performance Share Plan subject to a 2-year holding period Fuente

Los registros mensuales los redacta la IA a partir de los informes y fuentes oficiales verificados de cada mes (en inglés, tal como se extrajeron), y cada línea enlaza su fuente; las líneas argumentales agrupan hechos relacionados entre análisis mediante embeddings vectoriales (Amazon Titan Text Embeddings V2). Contexto provisional, no es asesoramiento de inversión.

Comparables del sector

Comparación con 36 empresas seguidas en Salud (mediana de ingresos +7,2% a/a), según datos XBRL de la SEC.

EmpresaÚltimos ingresosIngresos a/aMargen operativo
GSK plc GSK———
Unitedhealth Group Inc UNH113 mil M $-0,4%5,8%
Mckesson Corp MCK111 mil M $+7,6%1,4%
CVS Health Corp CVS108 mil M $+5,4%3,3%
Cigna Group CI73,7 mil M $+5,6%3,3%
Cardinal Health Inc CAH67,5 mil M $+5,5%1,1%
Elevance Health, Inc. ELV51,4 mil M $+1,4%2,5%

Último periodo reportado por empresa en SEC CompanyFacts (XBRL). Los calendarios fiscales pueden diferir.

Grandes fondos (13F)

FondoAccionesValorCambio en accionesTrimestre
Fidelity (FMR)64.920.926$3.127.240.971-0,1%T3 2026
Wellington Management9.650.852$464.881.541-15,3%T3 2026
State Street5.940.605$288.838.444-0,3%T3 2026
BlackRock3.408.608$164.192.624-5,8%T3 2026
D. E. Shaw & Co.1.954.472$94.146.916+91,7%T3 2026
Citadel Advisors1.165.967$56.164.631+669,2%T3 2026
Bridgewater Associates548.661$26.429.000+8,8%T3 2026
Renaissance Technologies466.340$22.463.598+49,8%T3 2026
Norges Bank (Norway's sovereign fund)200.000$10.484.000—T2 2026
Two Sigma Investments186.489$8.983.175+162,7%T3 2026
T. Rowe Price6.712.097$323.323-3,1%T3 2026
Millennium Management4067$224.458—T1 2026

De los informes trimestrales 13F-HR de los grandes fondos que seguimos, tal como se presentaron. Los fondos informan hasta 45 días después del cierre del trimestre, por lo que las posiciones pueden haber cambiado. Cambio: frente al trimestre anterior del mismo fondo. No es una recomendación.